StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Rating) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Performance GLMD opened at $3.16 on Friday. The company has a market cap of $5.31 million, a PE ratio […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Cambridge Investment Research Advisors Inc ,Institutional Trading Of Galmed Pharmaceuticals ,Raymond James Financial Services Advisors Inc ,News Ratings For Galmed Pharmaceuticals Daily ,Galmed Pharmaceuticals ,Galmed Pharmaceuticals Stock Performance ,Galmed Pharmaceuticals Company Profile ,Millennium Management ,Galmed Pharmaceuticals Ltd ,Get Rating ,Investment Research Advisors ,James Financial Services Advisors ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,